Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests
暂无分享,去创建一个
J. Deleuze | J. Thevenon | L. Faivre | C. Philippe | C. Thauvin-Robinet | Y. Duffourd | Pierre Vabres | É. Tisserant | M. Bardou | P. Callier | C. Binquet | L. Demougeot | C. Verstuyft | P. Kuentz | T. Jouan | A. Bruel | D. Lehalle | A. Mosca-Boidron | M. Lefebvre | S. Nambot | N. Jean-Marçais | M. Chevarin | E. Gautier | A. Pélissier | J. Delanne | A. Sorlin | A. Vitobello | M. Luu | E. Cretin | A. Chassagne | C. Peyron | C. Poé | F. Tran Mau-Them | Anne-Laure Mosca-Boidron
[1] Soma Das,et al. Scaling resolution of variant classification differences in ClinVar between 41 clinical laboratories through an outlier approach , 2018, Human mutation.
[2] Patrick Callier,et al. Clinical whole-exome sequencing for the diagnosis of rare disorders with congenital anomalies and/or intellectual disability: substantial interest of prospective annual reanalysis , 2017, Genetics in Medicine.
[3] K. Sangkuhl,et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update , 2017, Clinical pharmacology and therapeutics.
[4] Keith Nykamp,et al. Sources of discordance among germ-line variant classifications in ClinVar , 2017, Genetics in Medicine.
[5] Gil McVean,et al. The 100,000 Genomes Project Protocol , 2017 .
[6] Soma Das,et al. Clinical Laboratories Collaborate to Resolve Differences in Variant Interpretations Submitted to ClinVar , 2017, Genetics in Medicine.
[7] W. Chung,et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.
[8] R. Myers,et al. Genomic diagnosis for children with intellectual disability and/or developmental delay , 2016, bioRxiv.
[9] Stephen N. Thibodeau,et al. Whole‐Genome Sequencing in Healthy People , 2017, Mayo Clinic proceedings.
[10] Marylyn D. Ritchie,et al. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.
[11] Janet E Olson,et al. Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality. , 2016, The American journal of medicine.
[12] W. Chung,et al. Clinical application of whole-exome sequencing across clinical indications , 2015, Genetics in Medicine.
[13] Matthew S. Lebo,et al. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. , 2016, American journal of human genetics.
[14] I. Budin-Ljøsne,et al. Patient and interest organizations’ views on personalized medicine: a qualitative study , 2016, BMC medical ethics.
[15] D. Ledbetter,et al. Recommendations for the integration of genomics into clinical practice , 2016, Genetics in Medicine.
[16] Tao Wang,et al. Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.
[17] Sheri D Schully,et al. A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation , 2016, Genetics in Medicine.
[18] D. Adams,et al. Pharmacogenomic incidental findings in 308 families: The NIH Undiagnosed Disease Program experience , 2016, Genetics in Medicine.
[19] Gert Matthijs,et al. Guidelines for diagnostic next-generation sequencing , 2015, European Journal of Human Genetics.
[20] J. Berg,et al. A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing , 2015, Genetics in Medicine.
[21] Laurie D. Smith,et al. Whole-Exome Sequencing and Whole-Genome Sequencing in Critically Ill Neonates Suspected to Have Single-Gene Disorders. , 2016, Cold Spring Harbor perspectives in medicine.
[22] Laurie D. Smith,et al. Rapid whole genome sequencing and precision neonatology. , 2015, Seminars in perinatology.
[23] Jaekyu Shin,et al. Clinical application of pharmacogenetics: focusing on practical issues. , 2015, Pharmacogenomics.
[24] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[25] Avni Santani,et al. Actionable exomic incidental findings in 6503 participants: challenges of variant classification , 2015, Genome research.
[26] Gail P Jarvik,et al. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing , 2014, Genetics in Medicine.
[27] Xuan Yuan,et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders , 2014, Science Translational Medicine.
[28] Magalie S Leduc,et al. Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.
[29] L. Vissers,et al. Genome sequencing identifies major causes of severe intellectual disability , 2014, Nature.
[30] T. Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update , 2014, Clinical pharmacology and therapy.
[31] A. Rauch. Exome sequencing in unspecific intellectual disability and rare disorders , 2014, Molecular Cytogenetics.
[32] J. Vermeesch,et al. Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy. , 2014, Human reproduction.
[33] Magalie S Leduc,et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.
[34] Emily H Turner,et al. Actionable, pathogenic incidental findings in 1,000 participants' exomes. , 2013, American journal of human genetics.
[35] Claire Redin,et al. XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing. , 2013, American journal of human genetics.
[36] Megan Allyse,et al. Not-so-incidental findings: the ACMG recommendations on the reporting of incidental findings in clinical whole genome and whole exome sequencing. , 2013, Trends in biotechnology.
[37] Marc S. Williams,et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.
[38] B. Knoppers,et al. Whole-genome sequencing in health care , 2013, European Journal of Human Genetics.
[39] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update , 2013, Clinical pharmacology and therapeutics.
[40] B. V. van Bon,et al. Diagnostic exome sequencing in persons with severe intellectual disability. , 2012, The New England journal of medicine.
[41] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapy.
[42] E. Génin,et al. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening , 2009, Journal of Medical Genetics.